TNFR1 Blockers

High throughput screening (HTS) of venom and extremophile microorganisms extracts, have been initiated using our novel TNFR1 proprietary bioassay leading to the identification of multiple active venoms and extremophile extract.

The identification of the active molecules is ongoing. Already multiple venom fractions containing active peptides with sizes tractable by chemical synthesis have been identified.

The most promising hit molecules discovered by Inflamalps could enter into a lead optimization process. The best clinical candidate will be tested in Phase Ib in patients with atopic dermatitis.